LMR Partners LLP Reduces Holdings in Insulet Co. (NASDAQ:PODD)

LMR Partners LLP trimmed its position in Insulet Co. (NASDAQ:PODD - Free Report) by 65.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,155 shares of the medical instruments supplier's stock after selling 9,956 shares during the period. LMR Partners LLP's holdings in Insulet were worth $1,346,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new position in shares of Insulet in the fourth quarter worth $36,000. Itau Unibanco Holding S.A. purchased a new position in shares of Insulet in the fourth quarter worth $42,000. SRS Capital Advisors Inc. raised its holdings in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after buying an additional 56 shares during the last quarter. Assetmark Inc. raised its holdings in shares of Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after buying an additional 246 shares during the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Insulet by 117.3% in the fourth quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock worth $72,000 after buying an additional 149 shares during the last quarter.

Insulet Stock Up 0.8%

Shares of NASDAQ PODD traded up $2.73 during mid-day trading on Friday, reaching $324.75. The company had a trading volume of 836,387 shares, compared to its average volume of 706,773. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a 50 day simple moving average of $264.14 and a two-hundred day simple moving average of $266.45. The stock has a market cap of $22.85 billion, a P/E ratio of 56.09, a PEG ratio of 3.62 and a beta of 1.26. Insulet Co. has a 52-week low of $170.67 and a 52-week high of $325.22.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company's revenue was up 28.8% on a year-over-year basis. During the same period last year, the firm posted $0.73 EPS. Sell-side analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PODD. Oppenheimer raised their target price on shares of Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Barclays lifted their target price on shares of Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. Stifel Nicolaus lifted their target price on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a research report on Friday, February 21st. Raymond James reiterated an "outperform" rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Finally, StockNews.com downgraded shares of Insulet from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Insulet has a consensus rating of "Moderate Buy" and a consensus price target of $306.53.

Insider Buying and Selling

In other news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president now owns 23,180 shares in the company, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares of the company's stock, valued at $888,525. This trade represents a 36.10% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by company insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.